Presentation
7 March 2022 Intravascular dual-modality optical coherence tomography and multichannel near-infrared fluorescence inflammation imaging with the cathepsin-activatable LUM015 imaging agent
Author Affiliations +
Abstract
We report the use of our multimodal near-infrared fluorescence (NIRF) and OCT imaging system and catheter to perform the first imaging of LUM015 inflammatory activity in rabbit models of atherosclerosis in vivo. Using co-injection and multi-channel intravascular NIRF-OCT, we compared LUM015 (6.2 mg/kg) and preclinical ProSense (VM110, 3.5 mg/kg) fluorescence in the same subject. We found that co-registered fluorescence carpet maps were remarkably similar with a PCC of 0.51 and a Mander’s overlap coefficient of 0.79. Results suggest that LUM015 will be a viable clinical option for intracoronary imaging of plaque inflammatory activity in patients.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Andrew D. Thrapp, Mohamad B. Kassab, Joseph A. Gardecki, Osman A. Ahsen, Yoichiro Kawamura, Adam Mauskapf, Graham Spicer, Evangelia Gavgiotaki, Aditya Kumar, Maya Modi, Ara L. Bablouzian, Paola Leon, Aidan Burbridge, Benjamin Childs, Farouc A. Jaffer, and Guillermo J. Tearney "Intravascular dual-modality optical coherence tomography and multichannel near-infrared fluorescence inflammation imaging with the cathepsin-activatable LUM015 imaging agent", Proc. SPIE PC11936, Diagnostic and Therapeutic Applications of Light in Cardiology 2022, PC1193602 (7 March 2022); https://doi.org/10.1117/12.2605295
Advertisement
Advertisement
KEYWORDS
Inflammation

Luminescence

Optical coherence tomography

Imaging systems

In vivo imaging

Coherence (optics)

Fluorescence spectroscopy

Back to Top